This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (6)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

JAMA. 2000;283:597-598.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

MMWR. 1999;48:1165-1167

Staphylococcus aureus is one of the most common causes of hospital- and community-acquired infections. Nosocomial methicillin-resistant S. aureus (MRSA) infections have become common, and cases of community-acquired MRSA infections also have occurred.^1-2 Since 1996, vancomycin-intermediate S. aureus (VISA; vancomycin minimum inhibitory concentration [MIC] = 8-16 µg/mL) has been identified in Europe, Asia, and the United States.^3-5 The emergence of reduced vancomycin susceptibility in S. aureus increases the possibility that some strains will become fully resistant and that available antimicrobial agents will become ineffective for treating infections caused by such strains. This report describes the fourth case of confirmed VISA from a patient in the United States.

In April 1999, a 63-year-old woman with MRSA bacteremia (MIC <1 µg/mL) was transferred from a long-term-care facility to an Illinois hospital (hospital A). The patient had a history of frequent hospitalizations for complications of hemodialysis-dependent, end-stage renal disease, and intravascular access, . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Microarray Transcription Analysis of Clinical Staphylococcus aureus Isolates Resistant to Vancomycin
Mongodin et al.
J. Bacteriol. 2003;185:4638-4643.
ABSTRACT | FULL TEXT